tetano
Editor, Senior Moderator
Am J Ophthalmol
. 2023 Sep 20;S0002-9394(23)00381-1.
doi: 10.1016/j.ajo.2023.09.015. Online ahead of print. Non-infectious uveitis risk after Coronavirus Disease 2019 (COVID-19) vaccination: A nationwide retrospective cohort study
Myung Soo Chang[SUP] 1 [/SUP], Hae Rang Kim[SUP] 2 [/SUP], Sunyeop Kim[SUP] 3 [/SUP], Christopher Seungkyu Lee[SUP] 1 [/SUP], Suk Ho Byeon[SUP] 1 [/SUP], Sung Soo Kim[SUP] 1 [/SUP], Seung Won Lee[SUP] 4 [/SUP], Yong Joon Kim[SUP] 5 [/SUP]
Affiliations
Purpose: To investigate the incidence and risk of non-infectious uveitis (NIU) following Coronavirus Disease 2019 (COVID-19) vaccination compared to an unvaccinated, uninfected control group.
Design: Retrospective population-based cohort study METHODS: We included 5,185,153 individuals who received the first vaccine dose in the exposed group and 2,680,164 individuals in the unexposed, uninfected control group. The study observed for 180 days from their index date. Cumulative incidence and risk of NIU following COVID-19 vaccination, and attributable risk factors were assessed.
Results: Multivariable analysis showed elevated risk of non-anterior NIU within 60 days (hazard ratio (HR) = 1.27, 95% confidence interval (CI): 1.03-1.55) and 61-180 days (HR = 1.39, 95% CI: 1.20-1.62). Subgroup analysis highlighted increased risk in female for early and delayed non-anterior uveitis (HR = 1.44, 95% CI: 1.08-1.92; HR = 1.78, 95% CI: 1.43-2.20, respectively). Regardless of the location and onset timing of uveitis, a history of non-infectious uveitis was identified as the most significant risk factor, with a high hazard ratio ranging from 100 to 200.
Conclusions: COVID-19 vaccination may modestly increase the risk of non-anterior uveitis especially in females. Despite adjustments, bias may persist in the exposed group, owing to significant differences between unexposed and exposed groups and low incidence of non-anterior uveitis in the unexposed group. Future research should aim to refine these findings by assessing uveitis risk in prior NIU patients and by enlarging the sample size or cohort matching.
Keywords: COVID-19 vaccine; Vaccine associated uveitis; non-infectious uveitis.
. 2023 Sep 20;S0002-9394(23)00381-1.
doi: 10.1016/j.ajo.2023.09.015. Online ahead of print. Non-infectious uveitis risk after Coronavirus Disease 2019 (COVID-19) vaccination: A nationwide retrospective cohort study
Myung Soo Chang[SUP] 1 [/SUP], Hae Rang Kim[SUP] 2 [/SUP], Sunyeop Kim[SUP] 3 [/SUP], Christopher Seungkyu Lee[SUP] 1 [/SUP], Suk Ho Byeon[SUP] 1 [/SUP], Sung Soo Kim[SUP] 1 [/SUP], Seung Won Lee[SUP] 4 [/SUP], Yong Joon Kim[SUP] 5 [/SUP]
Affiliations
- PMID: 37739204
- DOI: 10.1016/j.ajo.2023.09.015
Purpose: To investigate the incidence and risk of non-infectious uveitis (NIU) following Coronavirus Disease 2019 (COVID-19) vaccination compared to an unvaccinated, uninfected control group.
Design: Retrospective population-based cohort study METHODS: We included 5,185,153 individuals who received the first vaccine dose in the exposed group and 2,680,164 individuals in the unexposed, uninfected control group. The study observed for 180 days from their index date. Cumulative incidence and risk of NIU following COVID-19 vaccination, and attributable risk factors were assessed.
Results: Multivariable analysis showed elevated risk of non-anterior NIU within 60 days (hazard ratio (HR) = 1.27, 95% confidence interval (CI): 1.03-1.55) and 61-180 days (HR = 1.39, 95% CI: 1.20-1.62). Subgroup analysis highlighted increased risk in female for early and delayed non-anterior uveitis (HR = 1.44, 95% CI: 1.08-1.92; HR = 1.78, 95% CI: 1.43-2.20, respectively). Regardless of the location and onset timing of uveitis, a history of non-infectious uveitis was identified as the most significant risk factor, with a high hazard ratio ranging from 100 to 200.
Conclusions: COVID-19 vaccination may modestly increase the risk of non-anterior uveitis especially in females. Despite adjustments, bias may persist in the exposed group, owing to significant differences between unexposed and exposed groups and low incidence of non-anterior uveitis in the unexposed group. Future research should aim to refine these findings by assessing uveitis risk in prior NIU patients and by enlarging the sample size or cohort matching.
Keywords: COVID-19 vaccine; Vaccine associated uveitis; non-infectious uveitis.